Wednesday, July 30, 2014 5:18:36 PM
General Session III: Emerging Therapies, Combos, and Targeted Agents
Changing arena of adjuvant therapy in malignant melanoma - Reinhard Dummer, MD, PhD
Ongoing clinical studies in BCC - Aleksandar Sekulic, MD, PhD
New systemic therapies in CTCL: Beyond the old paradigms - Steve Horowitz
Emerging treatment options in MCC: Chemotherapy and alternative approaches for metastatic disease - Shailender Bhatia, MD
General Session II: Current Treatment Algorithms in Cutaneous Malignancies
Current approaches to therapy in malignant melanoma: the US perspective - Antoni Ribas, MD
Current approaches to therapy in malignant melanoma: the EU perspective - Axel Hauschild, MD
Current treatment options for advanced BCC - Karl Lewis, MD
Current treatment options in CTCL - Pierluigi Porcu, MD
Update on NCCN guidelines for the management of MCC - Christopher K. Bichakjian, MD
http://www.cutaneousmalignancies.com/conference/agenda
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM